• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Request Free Sample ×
    ReportInfographic

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Italy RNA-based Therapeutics Market

    ID: MRFR/HC/50894-HCR
    200 Pages
    Garvit Vyas
    September 2025

    Italy RNA-Based Therapeutics Market Research Report By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Application (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) and By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Italy RNA-based Therapeutics Market Research Report — Global Forecast till 2035 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License
    Table of Contents

    Italy RNA-based Therapeutics Market Summary

    The Italy RNA-Based Therapeutics market is projected to grow significantly from 212.2 USD Million in 2024 to 525 USD Million by 2035.

    Key Market Trends & Highlights

    Italy RNA-Based Therapeutics Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 8.58% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 525 USD Million, indicating robust growth potential.
    • In 2024, the market is valued at 212.2 USD Million, reflecting a strong foundation for future expansion.
    • Growing adoption of RNA-based therapies due to increasing prevalence of genetic disorders is a major market driver.

    Market Size & Forecast

    2024 Market Size 212.2 (USD Million)
    2035 Market Size 525 (USD Million)
    CAGR (2025-2035) 8.58%

    Major Players

    Sarepta Therapeutics, OncoOne, BioNTech, Alnylam Pharmaceuticals, Axovant Gene Therapies, Rnai Pharmaceuticals, Moderna, VivaBioCelle, TheRNA immunotherapies, Regenxbio, Translate Bio, CureVac, Dicerna Pharmaceuticals, Silence Therapeutics

    Italy RNA-based Therapeutics Market Trends

    The RNA-Based Therapeutics Market in Italy is experiencing significant growth driven by advancements in molecular biology and increased funding for research and development. The Italian government has been supportive of bio-pharmaceutical innovations, with national funding mechanisms aimed at fostering collaborations between academic institutions and industry leaders. This backing enhances the research capabilities within the country and fosters a robust ecosystem for developing RNA-based treatments.

    Additionally, Italy's well-established pharmaceutical sector plays a crucial role in the market, encouraging local companies to invest more in RNA technology. Recent trends indicate a growing focus on personalized medicine, with RNA therapeutics being tailored to individual genetic profiles to address specific diseases. There is also a notable increase in clinical trials for RNA-based drugs, reflecting a shift toward targeted treatments for conditions such as cancer, genetic disorders, and infectious diseases, important areas of concern in Italy’s healthcare landscape.

    Furthermore, the surge in collaborations between biotechnology firms and academic institutions is fostering an innovation-rich environment that is conducive to breakthroughs in RNA therapeutics. Opportunities are present in expanding public and private partnerships, which could accelerate the commercialization of RNA-based therapies. Italian companies are encouraged to leverage the country's robust bio-pharmaceutical infrastructure and skilled workforce to tap into the global market.

    The increasing focus on rare diseases within the Italian healthcare system also presents a ripe opportunity for developing RNA therapies that are designed for niche markets. The evolving regulatory framework and increased understanding of RNA biology are paving the way for more efficient development processes, promising a dynamic future for the RNA-based therapeutics market in Italy.

    Italy RNA-based Therapeutics Market Drivers

    Market Segment Insights

    RNA-Based Therapeutics Market Technology Insights

    The Technology segment within the Italy RNA-Based Therapeutics Market has seen robust growth, driven by advancements in genetic research and the increasing prevalence of genetic disorders. RNA interference (RNAi) stands out prominently in this landscape, as it offers a targeted approach to gene silencing, holding transformative potential for treating various diseases, including cancers and viral infections. Antisense oligonucleotides (ASOs) also play a critical role, as they are designed to bind to specific RNA molecules, effectively modulating gene expression.

    This methodology not only highlights the significance of precision medicine but also demonstrates Italy’s commitment to advancing health outcomes through innovative therapeutic approaches. Moreover, the emergence of mRNA therapeutics, boosted by attention due to successful vaccine developments, leads to broader implications for treating infectious diseases and cancer therapies. The potential for mRNA platforms to enable rapid responses to health crises shows significant promise for the Italian bio-pharmaceutical sector.

    Lastly, CRISPR Technology remains a game changer in genetic editing, showcasing Italy's dedication to pioneering methods that could lead to groundbreaking treatments for genetic disorders. The intersection of these technologies fosters a rich environment for Research and Development (R&D) initiatives, supported by various public and private sectors in Italy, which aim to bring forth effective and scalable therapeutic solutions.

    As the RNA-Based Therapeutics Market continues to evolve in Italy, these technology segments will be pivotal in addressing unmet medical needs, enhancing treatment efficacy, and ultimately contributing to improved patient outcomes on a national and global scale.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    RNA-Based Therapeutics Market Application Insights

    The Application segment of the Italy RNA-Based Therapeutics Market plays a pivotal role in addressing critical health challenges faced by the population. This segment encompasses diverse areas such as Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases, each contributing significantly to the overall market landscape. Oncology remains a crucial focus due to the rising prevalence of cancer, driving research and innovation in RNA-based therapies designed to target specific cancer cells while minimizing damage to healthy tissue.

    Infectious Diseases represent another vital area, particularly in light of recent global health crises, highlighting the need for rapid-response therapeutics that can combat emerging pathogens effectively. The focus on Genetic Disorders is underscored by advancements in gene therapy techniques, giving hope to patients with previously untreatable hereditary conditions. Similarly, Cardiovascular Diseases are prioritized, as RNA-based solutions promise to address common issues such as heart disease and related complications, offering more tailored treatment options.

    These applications indicate a robust future for the Italy RNA-Based Therapeutics Market, fueled by the demand for personalized medicine and ongoing advancements in biotechnology.

    RNA-Based Therapeutics Market End Use Insights

    The End Use segment of the Italy RNA-Based Therapeutics Market plays a vital role in shaping the landscape of healthcare innovations within the region. Pharmaceutical companies are pivotal in the development and commercialization of novel RNA-based therapies, leveraging their extensive capabilities in research and development, clinical trials, and distribution networks. Their investments not only drive technological advancements but also enhance patient access to innovative treatments.

    Research institutions contribute significantly by advancing the fundamental understanding of RNA mechanisms, helping to identify new therapeutic targets and validate emerging RNA technologies. Furthermore, Contract Research Organizations, or CROs, provide essential support services to both pharmaceutical companies and research institutions, facilitating timely and cost-effective clinical trials. This interdependence among various participants in the market fosters a collaborative ecosystem that accelerates innovation in RNA therapeutics, a field crucial for addressing genetic disorders and improving healthcare outcomes in Italy.

    The market is expected to witness significant advancements driven by ongoing research and potential groundbreaking therapies that could reshape treatment paradigms.

    RNA-Based Therapeutics Market Delivery Method Insights

    The Delivery Method segment of the Italy RNA-Based Therapeutics Market is pivotal in ensuring effective therapeutic outcomes and improving patient experiences. Among the various methods, Liposomes are noteworthy due to their ability to encapsulate RNA molecules and enhance cellular uptake, significantly aiding targeted delivery. Nanoparticles are emerging as a dominant choice, owing to their versatile properties that enable controlled release and the ability to cross biological barriers, which is crucial for reaching specific tissues in the body effectively.

    Viral Vectors are also gaining traction as they provide a natural mechanism for delivering RNA into cells, making them efficient for gene therapy applications. Electroporation stands out for its ability to create temporary pores in cell membranes, facilitating the direct introduction of RNA therapeutics. Overall, the innovations in these delivery methods are enhancing the effectiveness of RNA-based therapies in Italy, as the market continues to grow and adapt to the needs for safer and more efficient treatment options.

    The Italy RNA-Based Therapeutics Market segmentation reflects a commitment to addressing the unique challenges in drug delivery, creating ample opportunities for advancements in patient care and therapeutic efficacy.

    Get more detailed insights about Italy RNA-based Therapeutics Market Research Report — Global Forecast till 2035

    Request Free Sample

    Regional Insights

    Key Players and Competitive Insights

    The Italy RNA-Based Therapeutics Market has been witnessing significant growth, influenced by advancements in biotechnology and increased investment in research and development. The market is characterized by a dynamic competitive landscape, with several key players striving to innovate and expand their product offerings. The rise in chronic diseases and the demand for personalized medicine have propelled various companies to focus on RNA-based therapeutics, offering novel solutions for treating genetic disorders, cancer, and infectious diseases.

    Competitive insights reveal that the market is driven by the need for effective, targeted treatments that harness the potential of RNA molecules, leading to a surge in collaborations, mergers, and strategic partnerships among industry participants. Companies are also focusing on improving delivery systems and enhancing the stability of RNA therapeutics to address challenges associated with their clinical application.

    Sarepta Therapeutics is prominently positioned within the Italy RNA-Based Therapeutics Market, known for its innovative approaches in developing therapies that address rare genetic disorders. The company's strength lies in its commitment to advancing RNA-targeted therapeutics, particularly gene therapies that utilize synthetic RNA constructs to promote muscle health and function. Sarepta's robust pipeline includes several investigational products aimed at treating conditions such as Duchenne Muscular Dystrophy, reflecting the company’s strong foothold in the market.

    In Italy, Sarepta has established significant collaborations with local research institutions and healthcare providers, enhancing its visibility and fostering a knowledge exchange that boosts its research capabilities. This strategic engagement not only solidifies Sarepta’s presence in the region but also contributes to the broader ecosystem of RNA-based therapeutic development.

    OncoOne is another key player in the Italy RNA-Based Therapeutics Market, specializing in innovative cancer therapeutics. The company is recognized for its focus on cancer detection and treatment solutions, particularly utilizing RNA in the development of diagnostic biomarkers and therapeutic agents. OncoOne's key products include personalized RNA-based therapies that target specific cancer pathways, leading to tailored treatment options based on individual patient profiles.

    The company has built a strong market presence through strategic partnerships and collaborations with Italian healthcare institutions, allowing it to leverage local expertise and resources in its research and development processes. Recent mergers and acquisitions have further strengthened OncoOne's position, enhancing its operational capabilities and expanding its portfolio of services. This strategic approach positions OncoOne as a significant contributor to the advancement of RNA-based therapeutics in Italy, underscoring its commitment to innovation in the oncology sector.

    Key Companies in the Italy RNA-based Therapeutics Market market include

    Industry Developments

    The Italy RNA-Based Therapeutics Market has witnessed significant developments in recent months, showcasing advancements and collaborations among key players. For instance, in October 2023, BioNTech announced a partnership with Italian research institutions to enhance RNA therapy for cancer treatment, signaling a commitment to local innovation. Meanwhile, Moderna continues to expand its footprint in Italy, particularly in the realm of messenger RNA-based vaccines and treatments.

    The growth of companies such as Alnylam Pharmaceuticals and Silence Therapeutics in the region has contributed to the market's valuation, with increasing investments and research initiatives. Notably, there have been no major merger or acquisition activities reported in Italy among the focused companies recently. However, Dicerna Pharmaceuticals recently received regulatory approval for its RNA-based therapy targeting rare genetic disorders, further highlighting the dynamic landscape of the market.

    The Italian government's support for biotechnology through funding initiatives and regulatory reforms has fostered a favorable environment for these companies to thrive. The combination of local research efforts and multinational partnerships is pivotal for driving growth and innovation within the RNA-Based Therapeutics sector in Italy.

    Market Segmentation

    RNA-Based Therapeutics Market End Use Outlook

    • Pharmaceutical Companies
    • Research Institutions
    • Contract Research Organizations

    RNA-Based Therapeutics Market Technology Outlook

    • RNA Interference
    • Antisense Oligonucleotides
    • mRNA Therapeutics
    • CRISPR Technology

    RNA-Based Therapeutics Market Application Outlook

    • Oncology
    • Infectious Diseases
    • Genetic Disorders
    • Cardiovascular Diseases

    RNA-Based Therapeutics Market Delivery Method Outlook

    • Liposomes
    • Nanoparticles
    • Viral Vectors
    • Electroporation

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 192.5(USD Million)
    Market Size 2024 212.25(USD Million)
    Market Size 2035 525.0(USD Million)
    Compound Annual Growth Rate (CAGR) 8.581% (2025 - 2035)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2024
    Market Forecast Units USD Million
    Key Companies Profiled Sarepta Therapeutics, OncoOne, BioNTech, Alnylam Pharmaceuticals, Axovant Gene Therapies, Rnai Pharmaceuticals, Moderna, VivaBioCell, eTheRNA immunotherapies, Regenxbio, Translate Bio, CureVac, Dicerna Pharmaceuticals, Silence Therapeutics
    Segments Covered Technology, Application, End Use, Delivery Method
    Key Market Opportunities Growing investment in biotech startups, Increasing demand for personalized medicine, Advancements in delivery technologies, Rising prevalence of genetic disorders, Expanding collaboration with research institutions
    Key Market Dynamics rising prevalence of genetic disorders, increasing investment in R&D, favorable regulatory environment, advancements in delivery technologies, growing demand for personalized medicine
    Countries Covered Italy

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Get In Touch
    Leave a Comment

    FAQs

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. Italy RNA-Based Therapeutics Market, BY Technology (USD Million)
    45. RNA Interference
    46. Antisense Oligonucleotides
    47. mRNA Therapeutics
    48. CRISPR Technology
    49. Italy RNA-Based Therapeutics Market, BY Application (USD Million)
    50. Oncology
    51. Infectious Diseases
    52. Genetic Disorders
    53. Cardiovascular Diseases
    54. Italy RNA-Based Therapeutics Market, BY End Use (USD Million)
    55. Pharmaceutical Companies
    56. Research Institutions
    57. Contract Research Organizations
    58. Italy RNA-Based Therapeutics Market, BY Delivery Method (USD Million)
    59. Liposomes
    60. Nanoparticles
    61. Viral Vectors
    62. Electroporation
    63. Competitive Landscape
    64. Overview
    65. Competitive Analysis
    66. Market share Analysis
    67. Major Growth Strategy in the RNA-Based Therapeutics Market
    68. Competitive Benchmarking
    69. Leading Players in Terms of Number of Developments in the RNA-Based Therapeutics Market
    70. Key developments and growth strategies
    71. New Product Launch/Service Deployment
    72. Merger & Acquisitions
    73. Joint Ventures
    74. Major Players Financial Matrix
    75. Sales and Operating Income
    76. Major Players R&D Expenditure. 2023
    77. Company Profiles
    78. Sarepta Therapeutics
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. OncoOne
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. BioNTech
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Alnylam Pharmaceuticals
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Axovant Gene Therapies
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Rnai Pharmaceuticals
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. Moderna
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. VivaBioCell
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. eTheRNA immunotherapies
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. Regenxbio
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Translate Bio
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. CureVac
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Dicerna Pharmaceuticals
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Silence Therapeutics
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. References
    163. Related Reports
    164. Italy RNA-Based Therapeutics Market SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2035 (USD Billions)
    165. Italy RNA-Based Therapeutics Market SIZE ESTIMATES & FORECAST, BY APPLICATION, 2019-2035 (USD Billions)
    166. Italy RNA-Based Therapeutics Market SIZE ESTIMATES & FORECAST, BY END USE, 2019-2035 (USD Billions)
    167. Italy RNA-Based Therapeutics Market SIZE ESTIMATES & FORECAST, BY DELIVERY METHOD, 2019-2035 (USD Billions)
    168. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    169. ACQUISITION/PARTNERSHIP
    170. MARKET SYNOPSIS
    171. ITALY RNA-BASED THERAPEUTICS MARKET ANALYSIS BY TECHNOLOGY
    172. ITALY RNA-BASED THERAPEUTICS MARKET ANALYSIS BY APPLICATION
    173. ITALY RNA-BASED THERAPEUTICS MARKET ANALYSIS BY END USE
    174. ITALY RNA-BASED THERAPEUTICS MARKET ANALYSIS BY DELIVERY METHOD
    175. KEY BUYING CRITERIA OF RNA-BASED THERAPEUTICS MARKET
    176. RESEARCH PROCESS OF MRFR
    177. DRO ANALYSIS OF RNA-BASED THERAPEUTICS MARKET
    178. DRIVERS IMPACT ANALYSIS: RNA-BASED THERAPEUTICS MARKET
    179. RESTRAINTS IMPACT ANALYSIS: RNA-BASED THERAPEUTICS MARKET
    180. SUPPLY / VALUE CHAIN: RNA-BASED THERAPEUTICS MARKET
    181. RNA-BASED THERAPEUTICS MARKET, BY TECHNOLOGY, 2025 (% SHARE)
    182. RNA-BASED THERAPEUTICS MARKET, BY TECHNOLOGY, 2019 TO 2035 (USD Billions)
    183. RNA-BASED THERAPEUTICS MARKET, BY APPLICATION, 2025 (% SHARE)
    184. RNA-BASED THERAPEUTICS MARKET, BY APPLICATION, 2019 TO 2035 (USD Billions)
    185. RNA-BASED THERAPEUTICS MARKET, BY END USE, 2025 (% SHARE)
    186. RNA-BASED THERAPEUTICS MARKET, BY END USE, 2019 TO 2035 (USD Billions)
    187. RNA-BASED THERAPEUTICS MARKET, BY DELIVERY METHOD, 2025 (% SHARE)
    188. RNA-BASED THERAPEUTICS MARKET, BY DELIVERY METHOD, 2019 TO 2035 (USD Billions)
    189. BENCHMARKING OF MAJOR COMPETITORS

    Italy RNA-Based Therapeutics Market Segmentation

     

     

     

    • RNA-Based Therapeutics Market By Technology (USD Million, 2019-2035)

      • RNA Interference
      • Antisense Oligonucleotides
      • mRNA Therapeutics
      • CRISPR Technology

     

    • RNA-Based Therapeutics Market By Application (USD Million, 2019-2035)

      • Oncology
      • Infectious Diseases
      • Genetic Disorders
      • Cardiovascular Diseases

     

    • RNA-Based Therapeutics Market By End Use (USD Million, 2019-2035)

      • Pharmaceutical Companies
      • Research Institutions
      • Contract Research Organizations

     

    • RNA-Based Therapeutics Market By Delivery Method (USD Million, 2019-2035)

      • Liposomes
      • Nanoparticles
      • Viral Vectors
      • Electroporation

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    No regional reports available for this market.

    No country-specific reports available for this market.

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials

    Global Magnesium Sulfate Market – Forecast till 2027